Drug intelligence / Profile preview

L6H21

Development stage: Unknown
Lead developer: Chiang Mai University

Overview

L6H21: sourced facts only. name: "The MD-2 inhibitor (L6H21) reduces systemic inflammation and metabolic disturbances in HFD-induced prediabetes." [PMID:34796473]; target: "The MD-2 inhibitor (L6H21) reduces systemic inflammation and metabolic disturbances in HFD-induced prediabetes." [PMID:34796473]; developer: "Neurophysiology Unit, Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand." [PMID:34796473]; stage: "In rats, L6H21 and metformin restored cognition and attenuated brain pathologies dose and time-dependently." [PMID:34796473]

Targets

LY96 (Myeloid differentiation factor 2)

Beyond the preview

Go deeper on L6H21.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on L6H21.